Abstract 3185
Background
Bone targeting agents (BTA) are prescribed for the prevention of skeletal-related events in patients with bone metastases from solid tumors. The use of BTA varies by region and little is known about use in Asia. This study evaluated the utilization patterns of BTA in patients within Taiwan, Hong Kong, and Korea.
Methods
This retrospective cohort study included patients diagnosed with a solid tumor (breast, prostate, or lung cancer) and with receipt of a BTA (intravenous zoledronate, pamidronate, or denosumab). All records were retrieved from databases including: the Taiwan National Health Insurance Database (NHID) of years 2012-2017, Korea’s NHID of years 2012-2016, and Hong Kong’s Clinical Data Analysis and Reporting System (CDARS) of years 2012-2017. Descriptive analyses were conducted to describe patient characteristics, the rate of BTA use among patients with a solid tumor by year and duration of BTA use in Taiwan, Hong Kong and Korea.
Results
We identified 18,286 (54% male), 2,861 (48% male) and 12,803 (41% male) patients with a solid tumor and BTA receipt in Taiwan, Hong Kong, and Korea, respectively. The mean age at BTA recipient was 64.1 (SD 13.7) in Taiwan, 64.3 (SD 12.8) in Hong Kong, and 61.5 (SD 12.9) in Korea. For patients with BTA use, the predominant tumor type was breast cancer in Taiwan (41%) and Korea (50%), and was lung cancer (53%) in Hong Kong. For the entire study period, the rates of BTA use among solid tumor patients were 8.3% in Taiwan, 5.9% in Hong Kong and 3.1% in Korea. The rates of BTA use increased gradually during study period in each place. In year 2016, the most prevalent BTA used was denosumab (7.7%) in Taiwan and zoledronate in Hong Kong (3.7%) and Korea (1.8%). Denosumab was not available in Korea during the study period. The mean duration of BTA use was 111 (SD 154) days in Taiwan, 110 (SD 148) in Hong Kong and 133 (SD 188) days in Korea.
Conclusions
In this first analysis reporting on treatment patterns for BTA use in Asia, the results suggest variation in BTA use among places and a shorter treatment duration of BTA use in clinical practice compared with guideline recommendations. The study provided fundamental information for subsequent evaluations of how this variation in BTA use may be associated with optimal clinical outcomes in Asia.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Funding
Amgen Asia Holding Limited (Hong Kong).
Disclosure
S.N. Gao: Research grant / Funding (institution): Amgen Asia Holding Limited (Hong Kong). N. Kleinman: Research grant / Funding (institution): Amgen Asia Holding Limited (Hong Kong). J. Lange: Research grant / Funding (institution): Amgen Inc., Thousand Oaks, CA, USA. T.C. Lin: Research grant / Funding (institution): Amgen Inc., Thousand Oaks, CA, USA. All other authors have declared no conflicts of interest.
Resources from the same session
3608 - Prognostic impact of Body Mass Index (BMI) on overall survival in patients with metastatic breast cancer
Presenter: Khalil SALEH
Session: Poster Display session 2
Resources:
Abstract
2686 - Clinicopathological characteristics, survival and prognostic factors of breast cancer-related microangiopathic haemolytic anemia: a multicenter study
Presenter: Marion Alhenc Gelas
Session: Poster Display session 2
Resources:
Abstract
1565 - Metabolic tumor volume by 18F-FDG PET/CT is an independent prognostic factor in metastatic breast cancer
Presenter: Heekyung Ahn
Session: Poster Display session 2
Resources:
Abstract
4498 - Patient Preferences for breast cancer treatments: A Discrete Choice Experiment from four European countries
Presenter: Thomais Konstantopoulou
Session: Poster Display session 2
Resources:
Abstract
1423 - Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study
Presenter: Diana Lüftner
Session: Poster Display session 2
Resources:
Abstract
2284 - Ventriculoperitoneal Shunt for CNS Metastasis in Breast Cancer: Clinical Outcomes Based on Intrinsic Subtype
Presenter: Hee Kyung Kim
Session: Poster Display session 2
Resources:
Abstract
4598 - Administration of chemotherapy for metastatic breast cancer near the end of life: a population registry study
Presenter: Luisa Edman Kessler
Session: Poster Display session 2
Resources:
Abstract
5706 - Prognostic value of histological growth pattern in patients operated for breast cancer liver metastases
Presenter: Ali Bohlok
Session: Poster Display session 2
Resources:
Abstract
1697 - Illness perceptions, quality of life and mood in metastatic breast cancer patients
Presenter: Isabel Domingues
Session: Poster Display session 2
Resources:
Abstract
1935 - Multidisciplinary Treatments Increases Overall Survival in Patients with Newly Diagnosed Stage IV Breast Cancer:An Analysis of 2010–2014 SEER Data
Presenter: Jian Zhang
Session: Poster Display session 2
Resources:
Abstract